期刊
CANCERS
卷 15, 期 23, 页码 -出版社
MDPI
DOI: 10.3390/cancers15235597
关键词
HNSCC; CMTM6; PD-L1; immune-checkpoint inhibitor; cisplatin; radiotherapy; tumor microenvironment
类别
In patients with head and neck squamous cell carcinoma (HNSCC), high expression of CMTM6 is associated with longer overall survival, regardless of treatment. CMTM6 is correlated with other immune markers, and patients with high expression of both CMTM6 and FOXP3 have the longest survival regardless of treatment. PD-L1 positivity is associated with longer progression-free survival, while lower levels of CTLA-4 and FOXP3 may be related to a good response to immunotherapy.
The 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) is approximately 65%. In addition to radio-chemotherapy, immunotherapy is an approach in the treatment of advanced HNSCC. A better understanding of the immune context would allow personalized treatment by identifying patients who are best suited for different treatment options. In our discovery cohort, we evaluated the expression profiles of CMTM6, PD-L1, CTLA-4, and FOXP3 in 177 HNSCCs from Caucasian patients of all tumor stages and different treatment regimens, correlating marker expression in tumor and immune cells with outcomes. Patients with CMTM6(high)-expressing tumors had a longer overall survival regardless of treatment. This prognostic benefit of CMTM6 in HNSCC was validated in an independent cohort. Focusing on the in the discovery cohort (n = 177), a good predictive effect of CMTM6(high) expression was seen in patients receiving radiotherapy (p = 0.07; log rank), but not in others. CMTM6 correlated with PD-L1, CTLA-4 and FOXP3 positivity, with patients possessing CMTM6(high)/FOXP3(high) tumors showing the longest survival regardless of treatment. In chemotherapy-treated patients, PD-L1 positivity was associated with longer progression-free survival (p < 0.05). In the 27 patients who received immunotherapy, gene expression analysis revealed lower levels of CTLA-4 and FOXP3 with either partial or complete response to this treatment, while no effect was observed for CMTM6 or PD-L1. The combination of these immunomodulatory markers seems to be an interesting prognostic and predictive signature for HNSCC patients with the ability to optimize individualized treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据